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Abstract 
Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-inflammation, acute 
respiratory distress syndrome, and multiple organ failure. Cytokine storm refers to a set of clinical 
conditions caused by excessive immune reactions and has been recognized as a leading cause of severe 
COVID-19. While comparisons have been made between COVID-19 cytokine storm and other kinds of 
cytokine storm such as hemophagocytic lymphohistiocytosis and cytokine release syndrome, the 
pathogenesis of cytokine storm has not been clearly elucidated yet. Recent studies have shown that 
impaired response of type-1 IFNs in early stage of COVID-19 infection played a major role in the 
development of cytokine storm, and various cytokines such as IL-6 and IL-1 were involved in severe 
COVID-19. Furthermore, many clinical evidences have indicated the importance of anti-inflammatory 
therapy in severe COVID-19. Several approaches are currently being used to treat the observed cytokine 
storm associated with COVID-19, and expectations are especially high for new cytokine-targeted 
therapies, such as tocilizumab, anakinra, and baricitinib. Although a number of studies have been 
conducted on anti-inflammatory treatments for severe COVID-19, no specific recommendations have 
been made on which drugs should be used for which patients and when. In this review, we provide an 
overview of cytokine storm in COVID-19 and treatments currently being used to address it. In addition, 
we discuss the potential therapeutic role of extracorporeal cytokine removal to treat the cytokine storm 
associated with COVID-19. 
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Introduction 
Coronavirus disease 2019 (COVID-19) has 
affected the world in a devastating way since 
December 2019. The causative virus, severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), 
has gained novel properties through variations in its 
original form. It now has great infectivity and is often 
fatal, causing acute respiratory distress syndrome 
(ARDS) and multiple organ failure [1]. In serious 
cases, clinical deterioration is often rapid, and in a 
large proportion the severe disease course is caused 
by systemic hyper-inflammation, the so called 
“cytokine storm” [2]. 
Cytokine storm is a condition of uncontrolled 
systemic hyper-inflammation caused by cytokine 
excess, leading to multi-organ failure and even death 
[3]. The concept of cytokine storm was initially 
recognized in acute graft-versus-host disease in the 
process of hematopoietic stem cell transplantation [4]. 
Researchers have since revealed that cytokine storm 
occurs in various diseases, such as malignancy, 
rheumatologic disease, and sepsis syndrome and is a 









treatments to mitigate cytokine storm have been 
introduced, no concrete treatment recommendations 
have been issued so far for COVID-19: in recent 
studies novel cytokine blockades targeting specific 
cytokines, such as interleukin (IL)-1 and IL-6 or Janus 
kinase (JAK) pathway have shown promising 
potential for the treatment of COVID-19. In addition, 
traditional anti-inflammatory drugs, including 
corticosteroids and colchicine, are also being explored 
for COVID-19 through active and vibrant researches 
[6]. 
In this study, we provide an overview of the 
cytokine storm caused by different etiologies and 
specific treatments thereof, focusing particularly on 
novel cytokine blockades. In addition, we discuss the 
pathophysiology and individual treatments for the 
cytokine storm in severe COVID-19. Last, we propose 
the potential of therapeutic plasma exchange (TPE) to 
treat cytokine storm in severe COVID-19. We believe 
that TPE is able to effectively remove inflammatory 
cytokines from the blood and can improve cytokine 
storm [7]. 
Immunopathogenesis of cytokine storm 
Immune features of cytokine storm 
Unpredicted adverse events in the phase 1 trial 
of the anti-CD28 monoclonal antibody TGN1412 
provided clues about cytokine storm [8]. In just a few 
hours after administration of the study medication, 
participants experienced serious complications from 
cytokine storm. The patients all commonly 
experienced sudden fever, respiratory and kidney 
failure, hypotensive shock, and diffuse coagulation 
disorders. Laboratory tests revealed anemia, 
neutrophilia, thrombocytopenia, and marked 
lymphopenia. These clinical features of multi-organ 
failure are believed to be caused by activation of the 
following four cascades: complement, kinin, clotting, 
and fibrinolysis systems [9]. In addition, acute 
increases in various cytokines were also noted in the 
early phase: tumor necrosis factor-alpha (TNF-α) was 
observed within an hour, followed by IL-1 [8]. 
Since then, through experience with various 
clinical diseases, including hemophagocytic lympho-
histiocytosis (HLH), the concept that an excessive 
immune response can seriously damage the body and 
causes rapid clinical deterioration began to be 
established [10]. Primary or familial HLH by genetic 
mutations and secondary HLH by specific viral 
infections, malignancies, autoimmune disorders, and 
iatrogenic causes are typical diseases accompanied by 
cytokine storm [11]. In particular, cytokine storm 
caused by autoimmune disorders is historically called 
macrophage activation syndrome (MAS) [12], and 
cytokine release syndrome (CRS) refers to the 
cytokine storm that occurs after chimeric antigen 
receptor (CAR) T cell therapy [13]. Sepsis is also an 
important cause for the development of cytokine 
storm, but it is not easy to discriminate cytokine storm 
from the clinical course of severe sepsis itself [14]. 
A variety of cytokines, including the IL-1 family, 
IL-6, IL-8, IL-10, TNF-α, and interferon (IFN)-γ, are 
involved in the development of a cytokine storm, 
although the key pathogenic cytokines appear to 
differ depending on the disease. IFN-γ is a key 
cytokine in primary HLH [15]. IL-1ß plays a major 
role in systemic juvenile idiopathic arthritis (SJIA) 
[16], while in MAS associated with SJIA, IL-18 may be 
a key cytokine [17]. Another representative cytokine, 
IL-6, is a key inflammatory molecule in CRS [18]. 
Importantly, even if the clinical symptoms caused by 
a cytokine storm exhibit a common pattern, treatment 
must be individualized because the degree to which 
each cytokine contributes to the development of the 
disease can differ [3]. On the other hand, cytokine 
storm in sepsis involves multiple factors, and thus, 
multi-directional suppression of inflammatory 
reactions is necessary. 
Interestingly, leukocytopenia, particularly 
lymphopenia, has been found to be a typical finding 
in cytokine storm and to be associated with the 
severity thereof. One study has described a possible 
mechanism for lymphopenia in cytokine storm. After 
the TGN1412 trial, Muller et al. administered another 
anti-CD28 super-agonistic antibody, JJ316, to 
experimental rats and observed responses [19]. 
Similar to those that occurred in the TGN1412 trial, 
including lymphopenia. Further investigations 
revealed that T cells were rapidly redistributed to 
secondary lymphoid organs, such as the spleen and 
lymph nodes, and were trapped with decreased 
mobility. Although we are not sure why these 
findings occur as a part of systemic 
hyper-inflammatory reactions, considering that 
lymphopenia was seen without infection in the trial, it 
is not likely that lymphopenia is induced directly by a 
pathogenic organism, such as a virus. Instead, we 
believe that lymphopenia might be the result of 
effective immune reactions against severe systemic 
infections for more efficient trafficking of immune 
cells to secondary lymphoid organs. One other 
notable thing from the TGN1412 trial is that the 
violent inflammatory responses were followed by 
reactive immunosuppression. The responses, called 
“second wave” or “immune paralysis,” were found to 
downregulate the previous inflammatory reactions, 
which is likely why TGN1412 was suspected as 
showing therapeutic effects on autoimmune disease 
in preclinical studies in rats [20]. 





Research has yet to reveal whether cytokine 
storm results from abnormal innate or adaptive 
immunity. As observed in the TGN1412 trial, rapid 
onset of cytokine storm after drug administration and 
a series of inflammatory responses following an acute 
increase of TNF-α suggests a problem with innate 
immunity [8]. However, considering the elevation of 
soluble interleukin-2 receptor in secondary HLH [21] 
and the effects of standard treatment for HLH 
targeting dysregulated T cells [22], the problem of 
adaptive immunity is also thought to be the main 
mechanism of cytokine storm. Among various 
cytokines related to cytokine storm, IL-1 and IL-6 
have been described as key cytokines in some 
patients. These cytokines are representative 
pro-inflammatory cytokines, along with TNF-α, that 
play an important role in acute phase responses of 
inflammation. Pattern recognition receptors (PRRs), 
such as toll-like receptor (TLR) and retinoic 
acid-inducible gene-1-like receptor (RLR), are proteins 
that present in the cytoplasm or cell membrane to 
recognize infection or tissue damage by combining 
with pathogen-associated molecular pattern (PAMP) 
derived from microorganisms or damage-associated 
molecular pattern (DAMP) resulting from tissue 
damage. IL-1, IL-6, and TNF-α are produced by 
dendritic cell and mononuclear macrophage that are 
activated by PRRs, and initiate a series of acute 
inflammatory reactions through activation of innate 
immunity [23]. Meanwhile, however, IL-6, along with 
IFN-γ, is also important for T-cell mediated adaptive 
immunity [24]. Therefore, dysregulated activation of 
T cells can be considered as a major pathological 
mechanism in a cytokine storm wherein IL-6 and 
IFN-γ are key cytokines. Taken together, although the 
clinical characteristics of cytokine storm are similar, 
underlying pathological mechanisms affecting the 
clinical course, prognosis, and treatment response in 
individual forms of cytokine storm can differ. Thus, it 
is important to find the key cytokine in various 
cytokine storms and to take a proper therapeutic 
approach by determining whether the instance is 
related with innate or adaptive immunity. 
Cytokine storm in severe COVID-19 
Studies have indicated that the rapid clinical 
deterioration and high mortality risk in severe 
COVID-19 could be related to cytokine storm [6]. One 
study showed that blood levels for various cytokines, 
such as IL-1ß, IFN-γ, IFN-γ-induced protein 10 (IP10), 
and monocyte chemoattractant protein 1 (MCP1), 
were elevated in COVID-19 [25]. In addition, patients 
admitted to the intensive care unit (ICU) had higher 
cytokine levels of IL-2, IL-7, IL-10, granulocyte 
colony-stimulating factor (G-CSF), IP10, MCP1, 
macrophage inflammatory protein 1- α, and TNF-α 
than those not requiring ICU treatment [25]. Another 
study showed that IL-6 was more elevated in non- 
survivors than survivors from COVID-19, suggesting 
that COVID-19 mortality might be due to virus- 
activated cytokine storm [26]. 
A recent article presented an interesting concept 
of a cytokine storm in COVID-19. The study argued 
that the cytokine storm in COVID-19 is the result from 
a failure of the immune system to remove the virus. 
They divided the cytokine storm into two stages [27]: 
The first stage is a temporary immune-deficient 
condition that is similar to primary HLH. The 
subsequent secondary stage is an overactive immune 
state to compensate for the target clearance failure, 
which appears as a clinical manifestation of a cytokine 
storm. Another review article also described the 
cytokine storm associated with COVID-19 in a similar 
context [28]. Cell and animal experiments 
investigating the effects of human coronavirus on 
cytokines have demonstrated delayed secretion of 
type Ⅰ and Ⅲ IFNs, including IFN α/ ß, in the early 
phase of infection and excessive secretion of 
pro-inflammatory cytokines from mononuclear 
macrophages in the later stage [29]. Another study in 
which immune analysis was performed in COVID-19 
patients highlighted profound impaired type 1 IFN 
responses characterized by a low level of IFN activity 
and downregulation of IFN stimulated genes. In 
addition, the study reported hyper-inflammatory 
responses represented by IL-6 and TNF-α [30]. Taken 
together, these studies emphasize that a failure in 
initial type-Ⅰ and Ⅲ IFN responses to SARS-CoV-2 
leads to an excessive late immune response and 
severe form of COVID-19 (Figure 1). In this respect 
we could figure out why severe COVID-19 is 
commonly accompanied by ARDS. The failure of 
immune response in initial period of SARS-CoV-2 
infection induces generalized hyper-inflammation in 
lung that leads to acute lung injury and ARDS. 
Many researchers believe that there are certain 
people who are vulnerable to cytokine storm in 
COVID-19, although clear evidence of this is lacking, 
at the moment. In support of this notion is a genetic 
predisposition to cytokine storm in primary HLH, 
which is already well documented. Primary HLH 
results from genetic defects in a perforin and 
granzyme dependent pathway in the action of natural 
killer (NK) cells and cytotoxic T lymphocytes [31]. 
Additionally, a few studies have also indicated 
genetic predispositions in other cytokine storm 
diseases. One study showed that some patients with 
SJIA carried perforin gene mutations related to reduce 
perforin activity [32]. Another study demonstrated 
that perforin expression was also reduced in patients 





with SJIA and could be restored following clinical 
improvement after stem cell transplantation [33]. 
Accordingly, we suspect there could be a genetic 
predisposition that makes some people more 
vulnerable than others to cytokine storm, leading to 
severe COVID-19 [34, 35]. To confirm this, more 
epidemiological studies on patients presenting with 
cytokine storm related to COVID-19 are needed in the 
future. 
Treatment of cytokine storm 
Treatments with specific cytokine inhibitors 
Current recommendations for the treatment of 
primary and secondary HLH are based on specific 
treatment protocols [22]. The mainstay of treatment is 
the use of corticosteroids, cyclosporine and etoposide, 
which are commonly used to target dysregulated T 
cells. The range of effects of these drugs is extensive 
and inhibits various mechanisms in the pathogenesis 
of HLH. Specific cytokine blockades have also proven 
successful in treating various types of HLH, although 
not as a general therapeutic option: it appears to only 
be effective when a target cytokine plays a key role in 
the disease. 
During the COVID-19 pandemic, many 
therapeutic drugs and interventions have been 
attempted to treat severe COVID-19 (Table 1). In light 
of successes in the treatment of various types of 
cytokine storm, a few cytokine blockades have been 
explored in the treatment of severe COVID-19 [36]. 
Inhibition of IL-1 signaling 
IL-1 is one of the major pro-inflammatory 
cytokines. It is comprised of two types of ligands, 
IL-1α and IL-1ß, of which IL-1ß plays a major role 
with systemic effects. IL-1 is primarily produced by 
innate immune cells, such as macrophages and 
monocytes. IL-1 exerts pro-inflammatory actions to 
recruit immune cells and to induce secondary 
cytokine production resulting in acute phase reactions 
(Figure 1). Some researchers argue that diseases 
caused by dysregulated IL-1 ought to be considered as 
auto-inflammatory diseases, not auto-immune 
diseases, because IL-1 is not directly involved in 
adaptive immunity, as with T and B cells [37]. 
Anakinra, a recombinant IL-1 receptor 
antagonist, has been effectively used to treat auto- 
inflammatory diseases, from rheumatoid arthritis to 
cytokine storm [38]. Another IL-1 inhibitor, 
canakinumab which is a human monoclonal antibody 
neutralizing IL-1ß, has also been found to be useful in 
treating various types of rheumatologic diseases, with 
the advantage of prolonged action [39]. Inhibition of 
IL-1 naturally exists as a feedback mechanism of 
self-regulation. Anakinra is a modified form of the 
human IL-1 inhibitor. In that context, the action of 
anakinra is expected to be safe because it is similar to 
its physiologic mechanism. Despite the infection risk, 
it is remarkably safe, relative to other agents in the 
same line. Furthermore, the effects of anakinra are not 
limited to the treatment of rheumatologic diseases. A 
re-analysis of a randomized controlled trial (RCT) 
demonstrated that anakinra reduces mortality in 
sepsis patients experiencing cytokine storm [40]. 
A few studies have suggested beneficial effects 
with the use of anakinra in COVID-19. A recent 
retrospective cohort study of patients with COVID-19 
and ARDS showed that high-dose anakinra could be 
used safely and improved respiratory function [41]. 
Another prospective cohort study of patients with 
severe COVID-19 pneumonia demonstrated that 
anakinra reduced the need for mechanical ventilation 
and mortality without serious side-effects [42]. 
Although both studies showed promising results for 
anakinra on severe COVID-19, further validation is 
needed through RCTs. 
 
Table 1. Therapeutic options for the treatment of cytokine storm in severe COVID-19 
Targeted inhibition Drugs or Interventions Previous established or alternative indications 
IL-1 Anakinra, Canakinumab RA, MAS-HLH 
IL-6 Tocilizumab, Sarilumab, Siltuximab RA, SJIA, CRS, Castleman disease 
TNF-α Etanercept RA, SJIA 
IFN-γ Emapalumab Primary HLH 
JAK Baricitinib, Ruxolitinib RA, MF, PV 
Non-selective Glucocorticoid Various autoimmune diseases and hematologic malignancies 
Non-selective Colchicine Gout 
Non-selective Mesenchymal stem cell Not yet documented, Regenerative medicine 
Non-selective Plasma exchange Various Ab-mediated diseases, Hyperviscosity syndrome 
Non-selective Intravenous  
immunoglobulin 
Various autoimmune and infectious diseases, Ab deficiency 
disorders  
Non-selective Convalescent plasma Not yet documented, Rescue therapy in severe infectious diseases 
Non-selective Radiation Tumor 
Ab: antibody; COVID-19: coronavirus disease 2019; CRS: cytokine release syndrome; HLH: hemophagocytic lymphohistiocytosis; IFN: interferon; IL: interleukin; JAK: Janus 
kinase; MAS: macrophage activation syndrome; MF: myelofibrosis; PV: polycythemia vera; RA: rheumatoid arthritis; SJIA: systemic juvenile idiopathic arthritis; TNF-α: 
tumor necrosis factor-alpha. 





Inhibition of IL-6 signaling 
IL-6 is an important pro-inflammatory cytokine 
that has pleiotropic effects. It is induced by infection 
or tissue injury and rapidly elicits acute reactions to 
minimize them. IL-6 promotes the production of 
various acute phase proteins in hepatocytes and 
induces the differentiation of immune cells, such as B 
and T cells (Figure 1). In addition, IL-6 is involved in 
the metabolism of iron by regulating hepcidin to 
make a microenvironment prohibitive against 
infection. Taken together, IL-6 plays a role in priming 
inflammatory responses and in activating adaptive 
immunity against infection or injury [24]. 
A few IL-6 inhibitors have been used in 
auto-immune disorders and related cytokine storm. 
Tocilizumab (TCZ), an anti-IL-6 receptor monoclonal 
antibody, has been used to treat various types of 
rheumatologic diseases, including rheumatoid 
arthritis, with excellent efficacy. Furthermore, it has 
been approved by the FDA in the management of CRS 
after CAR T-cell therapy [43]. On the other hand, it 
has not been found to show any effects against sepsis 
syndrome. 
Many studies have demonstrated that IL-6 is 
significantly elevated in patients with COVID-19. One 
study showed that IL-6 levels in COVID-19 patients 
were very high and comparable to those in CAR T cell 
CRS [44, 45]. Moreover, studies have suggested that 
IL-6 is predictive of poor outcomes in COVID-19. One 
study showed that non-survivors had higher IL-6 
levels than survivors [46], and another recent study 
suggested that a high level of IL-6 predicted the risk of 
requiring mechanical ventilation [47]. A recent 
prospective cohort study indicated that high levels of 
IL-6 and d-dimer reflected systemic inflammation and 
thrombotic condition, and predicted in-hospital 
mortality of COVID-19 [48]. 
Two IL-6 inhibitors are being attempted in 
treatment of COVID-19. In a few case series, 
sarilumab and tocilizumab have shown beneficial 
effects in reducing severity and mortality in severe 
COVID-19. A recent retrospective cohort study of 
1,351 patients with COVID-19 and pneumonia 
showed that tocilizumab significantly reduced the 
mechanical ventilation risk or death [49]. In an 
observational study of 154 patients requiring 
mechanical ventilation, tocilizumab reduced the risk 
of death by 45%. However, this study also showed 
that, with tocilizumab, the risk of superinfection 
significantly increased [50]. Although RCTs are 
required to validate these clinical effects, the outlook 
for these drugs in the treatment of COVID-19 seems 
encouraging. 
Inhibition of TNF-α signaling 
TNF-α is a cytokine primarily produced by 
activated macrophages in the acute inflammatory 
phase (Figure 1). In the TGN1412 trial, TNF-α was 
first to be elevated among several elevated cytokines 
[8]. Considering the role of TNF-α in the 
inflammatory response, TNF-α blockade is expected 
to have promising effects in various types of cytokine 
storm. However, in contrast to treatment of 
rheumatoid arthritis of rheumatoid diseases, its 
effectiveness has not been proven in the actual 
treatment of cytokine storm. While a few case reports 
have described the usefulness of TNF-α blockade with 
etanercept in MAS [51, 52], there are no relevant 
studies proving the effects systemically, and two 
studies failed to document beneficial effects for TNF-α 
blockade in sepsis syndrome [53, 54]. 
Anti-TNF-α therapy has not been actively 
attempted in COVID-19. Reports of COVID-19 
infection in patients who maintain anti-TNF-α 
therapy against existing inflammatory bowel disease 
have suggested that anti-TNF-α therapy maintenance 
is safe; however, clear evidence of clinical 
improvement therewith is lacking [55]. A recent 
interesting study showed that TNF-α mediated acute 
lung injury was reduced by using an aptamer 
targeting TNF-α. Considering that acute lung injury is 
a characteristic finding in COVID-19, this study 
provides a possible therapeutic approach to treating 
COVID-19 cytokine storm accompanied by lung 
injury [56]. 
Inhibition of IFN-γ signaling 
IFN-γ is secreted by several immune cells, 
including macrophages, NK cells, and T cells, and 
plays a role in stimulating the main inflammatory 
effector cells directly (Figure 1). Thus, IFN-γ is 
considered a major effector cytokine in various 
cytokine storm disorders. In particular, IFN-γ is a key 
cytokine in primary HLH, which is caused by 
hyperactivity of the immune system in response to a 
failure to eliminate pathogens due to perforin defects. 
In HLH, IFN-γ is excessively stimulated and leads to a 
cytokine storm. Emapalumab, an anti- IFN-γ 
monoclonal antibody, has been used to treat primary 
HLH since it was approved by the FDA in 2018 [57]. 
Several studies have documented clinical effects for 
emapalumab by confirming decreases in blood levels 
of C-X-C motif chemokine ligand 9 (CXCL9), an IFN-γ 
derived chemokine that is a good indicator to measure 
IFN-γ activity after use of emapalumab. A recent 
interventional study indicated that emapalumab had 
clinical effects without specific side effects in primary 
HLH treatment [58]. Another study described clinical 
effects for emapalumab in refractory HLH caused by 





Epstein–Barr virus (EBV) infection [59]. Interestingly, 
the study indicated that excess IFN-γ contributed to 
immune paralysis and that emapalumab could reduce 
cytokine storm and effectively clear persistent EBV by 
reversing immune paralysis. For treating COVID-19, 
there are no significant trials supporting the use of 
IFN-γ inhibitors yet. Instead, many researchers have 
attempted to administer type 1 IFNs, such as IFN α, ß 
and κ, in the early phase of COVID-19 [60, 61], as 
recent studies have suggested that decreased type Ⅰ 
and Ⅲ IFNs response to SARS-CoV-2 plays an 
important role in the development of the observed 
cytokine storm associated with COVID-19 [62]. 
Inhibition of JAK pathway 
JAK is an intracellular tyrosine kinase that 
mediates signals from cytokines, hormones, and 
growth factors. The Janus kinase-signal transducer 
and activator of transcription (JAK/STAT) pathway is 
commonly involved in various cytokine activation 
processes (Figure 1). JAK inhibitors, including 
ruxolitinib and baricitinib, have been used to treat a 
variety of autoimmune and hematology diseases. JAK 
inhibition is thought to be able to effectively suppress 
cytokine storm because it can non-selectively inhibit 
the activity of many cytokines. On the other hand, 
non-selective inhibition of the immune response poses 
a risk of secondary infection, because it also 
suppresses the innate immune system that fights 
against pathogenic microorganisms, such as viruses, 
bacteria, or fungi. Moreover, because the JAK/STAT 
pathway is involved in several physiological 
mechanisms other than the immune response, 
inhibition of these pathways can potentially lead to 




Figure 1. Pathophysiology and treatment of cytokine storm in COVID-19. Type-1 IFNs play a major role in inhibiting the early stage of COVID-19 infection. Dendritic cells and 
mononuclear macrophages that recognize viral antigens induce an acute phase response through pro-inflammatory cytokines such as IL-6, IL-1, and TNF-α. Among them, IL-6 
stimulates T-cells to activate adaptive immunity. Activated T cells also stimulate macrophage and NK cells through IFN-γ to promote virus removal. Failure of the initial immune 
response by type-1 IFNs increases excessively the activity of immune system leading to cytokine storm. Aerosolized type-1 IFNs promotes an initial immune response to remove 
virus, corticosteroids and novel cytokine blockades inhibits immune responses to prevent cytokine storm. ACE2: angiotensin converting enzyme-2; COVID-19: coronavirus 
disease 2019; IFN: interferon; IL: interleukin; JAK/STAT; Janus kinase-signal transducer and activator of transcription; NK: natural killer; RLR: retinoic acid-inducible gene-1-like 
receptor; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TCR: T cell receptor; TCZ: tocilizumab; TLR: toll-like receptor; TNF-α: tumor necrosis factor-alpha. 
  





JAK inhibition in COVID-19 appears to offer two 
clinical advantages. JAK inhibitors block cytokine 
signaling, thereby reducing excessive inflammatory 
responses, as well as the entry of SARS-CoV-2, in the 
early phase of infection [63]. As is well known, 
SARS-CoV-2 enters the body through angiotensin 
converting enzyme-2 (ACE2) on alveolar type 2 cells 
in the lungs, and several regulators are involved in 
mediating endocytosis and intracellular transport 
through ACE2. AP2-associated protein kinase-1, one 
such regulator, is also a target of JAK inhibitors, 
particularly baricitinib. Thus, JAK inhibitors can 
impede the entry and proliferation of SARS-CoV-2 
[64]. Accordingly, several JAK inhibitors, including 
baricitinib, ruxolitinib, and fedratinib, are being 
studied in the treatment of severe COVID-19. A recent 
multi-centered RCT of ruxolitinib in patients with 
COVID-19 noted faster clinical improvement with the 
drug, although the results lacked statistical 
significance [65]. Another multi-centered 
retrospective study demonstrated that baricitinib 
reduced the rate of ICU admission and fatality and 
increased discharge rates [66]. 
Other anti-inflammatory or immuno-
suppressive agents 
In addition to cytokine blockade, various 
anti-inflammatory therapies are being applied in an 
attempt to treat COVID-19. This trends show that 
anti-inflammatory treatment is as important as 
anti-viral treatment in the treatment of COVID-19. As 
with any serious illness, many clinicians are currently 
using glucocorticoids as an empirical treatment for 
severe COVID-19. Unlike specific cytokine inhibitors, 
glucocorticoids are believed to be effective against 
cytokine storm by inhibiting multiple inflammatory 
targets (Figure 1). Glucocorticoids not only have 
excellent immunosuppressive effects on immune 
cells, but also have anti-inflammatory effects by 
inhibiting the production of major inflammatory 
molecules, including prostaglandins and leukotrienes. 
Evidence supporting the use of glucocorticoids in 
severe COVID-19, however, is lacking [67, 68]. 
Although this matter is still argued, several studies 
have positively reported steroid effects in severe 
COVID-19 [69, 70]. 
Colchicine is an anti-inflammatory drug that is 
commonly used in gouty arthritis. The main action of 
colchicine is to impede the function of neutrophils, 
and it has the effect of inhibiting IL-1ß activity by 
inhibition of the inflammasome complex. A few 
studies are investigating the clinical effects of 
colchicine on COVID-19 [71]. A recent RCT 
demonstrated that colchicine delays the time to 
clinical deterioration in COVID-19 [72]. 
Some clinicians have attempted to use stem cells 
for the treatment of severe COVID-19 [73]. Although 
the effectiveness of stem cell therapy in existing 
immune diseases has not been clearly demonstrated, 
researchers have argued that stem cell therapy has 
immunomodulatory effects and helps to differentiate 
immune cells. 
Interestingly, a few researchers have proposed 
the use of low-dose radiation therapy to control 
hyper-inflammatory states in severe COVID-19 [74, 
75]. According to the cited studies, low-dose radiation 
(usually < 1.0 Gy) has immune-modulating effects on 
immune cells, changing them into an anti- 
inflammatory phenotype. Thus, in the patients with 
COVID-19 and ARDS, low-dose radiation on both 
lungs could potentially facilitate clinical 
improvements in hyper-inflammatory lung injury. 
Several drugs have been experimentally shown 
to be effective in reducing cytokine storm associated 
with influenza infection, which is similar to 
COVID-19. Peroxisome proliferator-activated 
receptors (PPARs) agonists, cyclooxygenase (COX) 
inhibitors [76], and sphingosine-1-phosphate receptor 
1 (S1P1) [77] agonists have been shown in several 
experimental studies to be effective in hindering 
cytokine storm in severe influenza infections. 
Although S1P1 agonist is known to induce 
lymphopenia, one study suggested that it might be 
helpful to mitigate the cytokine storm induced ARDS 
by preventing trafficking of immune cells to the lungs 
[78]. A recent review described the use of 
nanomedicine to modulate macrophage dysfunction 
in cytokine storm. According to the researches, 
dysfunctional macrophage is critical in the 
pathogenesis of cytokine storm, and thus selectively 
inhibiting dysregulated macrophages using 
liposomes or synthetic nanoparticles can be a novel 
therapeutic approach for the treatment of cytokine 
storm [79]. However, the use of these drugs in these 
instances is not supported by evidence in human 
subjects and clinical trials, and requires substantial 
clinical data. 
Issues with treatment of cytokine storm 
associated with COVID-19 
Several studies have shown that cytokine plasma 
concentrations exhibit diurnal variations. According 
to a meta-analysis study, IL-6 concentrations are 
lowest in the morning and peak twice during the time 
from afternoon to morning [80]. Another study 
showed that several cytokines, including IL-6 and 
IL-1, had higher concentrations in the afternoon than 
in the morning [81]. Both studies commonly proposed 
diurnal variations in cortisol as a contributing factor 
to the diurnal variations in the cytokines. It also seems 





that they may also be affected by different 
physiological mechanisms that have not yet been 
identified. Therefore, diurnal variations in these 
cytokines should be considered in the diagnosis and 
treatment of cytokine storm and regarded as an 
important factor when determining the appropriate 
timing of drug administration in cytokine-targeted 
therapy. 
The cytokine storm caused by COVID-19 
appears to be more similar to that in sepsis syndrome 
than that in HLH in hematologic or rheumatologic 
diseases. The cytokine storm related to COVID-19 was 
caused by infection as in the case of sepsis syndrome. 
As the cytokine storm caused by infections is likely 
involving more complex mechanisms than that by 
non-infectious causes, the effect of targeted treatment 
on a specific cytokine may be limited. Nonetheless, 
the results of ongoing research do not seem to be 
discouraging, and additional verification through 
RCTs is required. 
Treatment of COVID-19 is largely divided into 
two parts: antiviral treatment to inhibit SARS-CoV-2 
replication and anti-inflammatory treatment to reduce 
systemic inflammation. Treatment of the cytokine 
storm belongs to the latter, and new targeted 
therapies for cytokines and corticosteroids have been 
attempted. Anti-inflammatory therapy in severe 
COVID-19 poses one critical issue. Anti-inflammatory 
treatment is aimed at clinical improvement through 
suppression of excessive immune responses; while on 
the other hand, the immunosuppressive effect of anti- 
inflammatory treatment paradoxically decreases the 
clearance of the virus from the body and increases the 
risk of secondary bacterial infections. In influenza 
infections, despite no definitive conclusion on their 
effects and risks, steroids are considered empirical 
drugs in severe cases. During influenza pandemic 
periods, many clinicians use steroids to treat serious 
clinical complications, including ARDS [82]. To 
compensate for decreased capacity of viral eradication 
and to avoid the risk of secondary bacterial infections, 
simultaneous administration of anti-viral agents (e.g., 
oseltamivir) and broad-spectrum antibiotics are 
essential in severe influenza infection [83]. On the 
contrary, the anti-inflammatory treatment for severe 
COVID-19 is in a very disadvantageous position, 
because there is no proven effective anti-viral agent at 
the moment. Although an observational study and a 
preliminary report from an RCT on the effectiveness 
of the use of remdesivir in severe COVID-19 have 
recently been released, further verification through 
complete and reliable RCTs is required [84, 85]. In 
COVID-19, immunosuppressive agents, including 
cytokine blockades and steroids, should be used 
appropriately only when an excessive immune 
response is evident, and thus, a proper clinical 
diagnosis of cytokine storm is essential. 
Early detection of cytokine storm and immediate 
initiation of treatments to reduce severity are essential 
for the treatment of severe COVID-19. A recent report 
focused on the rheumatologist’s role in COVID-19 era, 
providing guidelines for the early diagnosis of 
cytokine storm, and suggested the need for 
cooperation with rheumatologists as professionals 
with experience in treating cytokine storm and in 
using various immunosuppressants [86]. Meanwhile, 
many studies have emphasized the importance of 
hyperferritinemia in early diagnosis of cytokine storm 
[6]. Serum ferritin can be easily measured in clinical 
laboratories and reflects inflammatory states well. 
Despite the lack of cut-off values, a significant 
elevation in ferritin and typical clinical features are 
suggestive of cytokine storm in COVID-19 [86]. 
Cytokine removal by blood purification 
The efficacies of various immunosuppressive 
measures on cytokine storm are under investigation. 
While we are eagerly awaiting such results, other 
therapeutic measures that are able to reduce cytokine 
levels within hours of application are readily 
available. Direct removal of such pro-inflammatory 
stimuli might reduce the likelihood of progressive 
organ damage [87], a hallmark of COVID-19. 
Many studies have investigated the removal of 
inflammatory cytokines through blood purification 
[88]. Continuous renal replacement therapy (CRRT), 
as a type of hemofiltration or hemodiafiltration 
method, has shown clinical benefits from removing 
inflammatory molecules, beyond just replacing 
impaired kidney function. Previous studies have 
demonstrated that high doses of hemofiltration 
afforded better outcomes than standard doses in 
critical patients. These results suggest that high 
clearance of inflammatory cytokines might exert 
clinical benefits [89]. Meanwhile, a systemic review 
investigating the effects of extracorporeal cytokine 
removal has indicated that high cut-off techniques 
remove cytokines more effectively through the larger 
pores of the membrane [90]. 
Application of therapeutic plasma exchange in 
the treatment of cytokine storm 
TPE is a more specific method to remove 
molecules more effectively from plasma than CRRT. It 
is usually used to treat antibody-mediated severe 
diseases, such as thrombotic microangiopathies, 
glomerulonephritis forms, Guillain-Barré syndrome, 
and others [91]. Although TPE is not accepted as a 
standard treatment for HLH, a few studies have 
suggested a promising role for TPE in primary and 





secondary HLH. One study showed that 
inflammatory states were reduced after TPE therapy 
in children with hyperferritinemia and secondary 
HLH [92], and another case study reported that TPE 
facilitated a rapid improvement in patients with 
hemophagocytic syndrome during HLH-2004 
protocol based standard therapy [93]. A recent case 
series showed that early use of TPE along with 
immunosuppressive therapy was an effective 
treatment strategy for steroid refractory MAS-HLH 
[94]. 
TPE has also been used as an alternative 
treatment for severe sepsis (Table 2). Nevertheless, 
there is no clear evidence to recommend the use of 
TPE in severe sepsis yet, because the available trials 
have shown conflicting results [95, 96]. Still, a few 
studies support the role of TPE in sepsis. A 
well-conducted systemic review indicated that TPE 
could reduce mortality in adult patients with sepsis 
[97]. A recent non-randomized prospective study 
demonstrated that early TPE was associated with a 
rapid reduction of norepinephrine in septic shock, 
maintaining mean arterial pressure above 65 mmHg. 
Furthermore, it could also reduce pro-inflammatory 
cytokines (IL-6, IL-1ß, and angiopoietin-2) [98]. 
Another investigation involving subjects with septic 
shock demonstrated that TPE partially reversed 
coagulation disorders in patients requiring high doses 
of norepinephrine [99]. 
In regard to TPE use in cytokine storm, TPE has 
several strengths. First, TPE can elicit immediately 
clinical effects in rapidly deteriorating cytokine storm. 
Early use of TPE may compensate for relatively slow 
action of immunosuppressants. Second, TPE exhibits 
non-selective properties in the elimination of 
inflammatory cytokines. It is believed that non- 
selective removal of cytokines is particularly suitable 
for the treatment of sepsis-induced cytokine 
syndrome [100], because the occurrence of a cytokine 
storm related to sepsis is believed to be the result of a 
complex mechanism involving various inflammatory 
factors [101]. In that context, we prefer centrifugal- 
type TPE over filtration-type, because centrifugal TPE 
is less selective in separating plasma, although we still 
believe that TPE itself could provide clinical benefits 
regardless of the type. A previous study in the 
patients with Guillain-Barré syndrome also 
demonstrated that centrifugal TPE had shorter time to 
onset and greater clinical effects than double filtration 
plasmapheresis [102]. Last, bulk removal of cytokines 
by TPE could obviate negative effects on immune cells 
and improve the function of monocytes and/or 
macrophages, thereby reversing immune paralysis. 
Overall, the immunomodulation effects by TPE could 
reinforce the immunity against COVID-19 and 
provide the chance of overcoming cytokine storm by 
increasing susceptibility to simultaneously 
administered immunosuppressants [100]. 
Proposal for the use of therapeutic plasma 
exchange in COVID-19 
Influenza infection as a viral disease is more 
similar to COVID-19 than bacterial sepsis. Severe 
COVID-19 has clinical features similar to severe 
influenza infection, characterized by acute lung injury 
and multiple organ failure. A few case studies have 
reported that TPE could be helpful in serious 
influenza infections. One case study showed that 
three children with severe influenza infections were 
able to recover from acute respiratory failure and 
hemodynamic shock through a rescue therapy 
comprising three consecutive sessions of TPE [103]. 
Another case study showed that three patients with 
influenza-associated encephalopathy had markedly 
improved with two to three sessions of TPE every 
other day in combination with methylprednisolone 
injections (30 mg/kg). In addition, the study indicated 
that a key pro-inflammatory cytokine, IL-6, was 
significantly reduced in blood and cerebrospinal fluid 
after repetitive TPE [104]. 
 
Table 2. Studies on the effects of therapeutic plasma exchange in severe sepsis or septic shock 
Authors (year) Type of Study Subjects Clinical outcomes 
Reeves et al. (1999) Multicenter, Prospective, RCT Adults (n, 22);  
Children (n, 8) with sepsis 
No significant difference in mortality at 14-day; No significant reduction 
in the risk of death in TPE; No effects on IL-6, G-CSF, and thromboxane-B. 
Busund et al. (2002) Single-center, Prospective, RCT Adults (n, 106) with septic shock Mortality at 28-day: TPE vs. Control; 33·3 vs. 53·8 (%) (p=0·050);  
Absolute risk reduction: 20·5%. 
Nguyen et al. (2008) Single-center, Prospective, RCT Children (n, 10) with Thrombocytopenia 
and MOF 
Improved ADAMTS-13 activity and organ function; at median 12-day in 
TPE group (p<0·05). 
Rimmer et al. (2014) Systemic review Meta-analysis Four RCTs 
including children and adults 
No significant reduction of all-cause mortality in overall patients; 
But, significant reduction of all-cause mortality in adult patients; 
(Risk Ratio 0·63, CI 0·42-0·96) 
CI: confidence interval; G-CSF: granulocyte colony-stimulating factor; IL: interleukin; JAK: Janus kinase; MOF: multiple organ failure; RCT: randomized controlled trial; TPE: 










Table 3. Case studies on the effects of therapeutic plasma exchange in COVID-19 
Authors Subjects Prescription of TPE a Clinical outcomes 
Keith et al. One patient with pneumonia, shock, and multi-organ 
failure 
1/ 4.5L/ FFP Improved respiratory condition and hypotensive shock, 
increased heart function 
Shi et al. One patient with ARDS, shock 3/ 6L/ FFP Improved respiratory condition and hypotensive shock 
Morath et al. Five patients with respiratory failure 1~2/ 3.39L/ FFP Improved respiratory condition and hypotensive shock, 
Decrease in inflammatory marker (IL6, ferritin, D-dimer) 
Adeli et al. Eight patients with ARDS and shock 3~5/ 2L/ FFP, albumin Improved respiratory condition 
Dogan et al. Six patients with COVID-19-related autoimmune 
meningoencephalitis 
1~3/ no data/ albumin Clinical improvement including meningoencephalitis, Decrease 
in serum ferritin 
Khamis et al. Eleven patients with ARDS or pneumonia 5/ one times body plasma 
volume/ FFP 
Higher extubation rate, lower mortality at 14 and 28 days 
compared to non-TPE cases 
a Prescription of TPE is presented as total number of trials/ dose per session/ type of substitution fluid. ARDS: acute respiratory distress syndrome; COVID-19: coronavirus 
disease 2019; FFP: fresh frozen plasma; IL: interleukin; TPE: therapeutic plasma exchange. 
 
 
Currently, remdesivir is being considered as a 
potential drug for treating COVID-19; however, in 
severe COVID-19, both antiviral treatment that 
suppresses the activity of the virus and 
anti-inflammatory treatment that can reduce 
excessive inflammation in the body are essential. In 
our eyes, rescue therapy comprising TPE as an 
alternative treatment early in serious cases with signs 
of a rapid worsening disease course and features of 
cytokine storm might be warranted. Despite the lack 
of a solid basis for the availability of TPE, even in 
severe infectious conditions such as sepsis, we believe 
that practical experiences with TPE use in various 
clinical diseases provide clues on TPE availability. 
Furthermore, the simple and reasonable hypothesis 
that, by exchanging plasma, cytokines and viruses can 
be effectively eliminated is worth considering. In this 
regard, a recent case report described the effects of 
TPE on COVID-19 [105]. In that case report, a patient 
with severe respiratory failure and anti-phospholipid 
syndrome by COVID-19 was given three sessions of 
plasma exchange. After plasma exchange, the patient 
showed clinical improvements with reduced titers of 
antiphospholipid antibodies and inflammatory 
markers, including IL-6. Another case series 
demonstrated that TPE had effects on treating 
COVID-19-related autoimmune meningoencephalitis 
[106]. In that report, ferritin levels reflective of 
hyper-inflammatory states were reduced significantly 
after repetitive plasma exchange. Other than that, a 
few case studies of COVID-19 patients with ARDS 
and shock have indicated that TPE dramatically 
improved clinical conditions and inflammatory 
markers, even after small numbers of trials [107-110]. 
A recent observational cohort study also showed that 
TPE afforded clinical benefits of a higher extubation 
rate and lower mortality rate at 28-day in COVID-19 
patients with respiratory failure than non-TPE cases 
[111]. Currently, while there are increasing case 
reports indicating the usefulness of TPE use in severe 
COVID-19 (Table 3) and while many clinicians might 
be using it in clinical practice, RCTs are still required 
to attain relevant clinical evidence in support thereof 
[112]. 
There are several clinical issues with the use of 
TPE in COVID-19. First, it poses risks of bleeding and 
catheter infection. In addition, it can cause electrolyte 
imbalances, such as hypocalcemia and hypokalemia, 
depending on the type of anti-coagulating agents or 
replacement fluids. TPE can also occasionally induce 
unpredicted anaphylactic shock due to the use of 
blood materials. However, the incidences of these 
complications are thought to be relatively small, and 
most cases can be controlled with medical support. 
Although TPE can be applied without technical 
difficulties in experienced centers, active involvement 
of medical staff in this procedure and capacity issues 
(most centers are limited with machines) only allow 
for the use of TPE in selected patients. Above all, the 
primary critical issue with TPE in COVID-19 is that 
the use of non-convalescent plasma as a substitution 
fluid could reduce protective antibodies against 
SARS-CoV-2. According to the clinical experiences of 
a few researchers, SARS-CoV-2-specific IgG and IgA 
antibodies were detected in waste bags, and 
circulating antibodies were also reduced during TPE 
application [113]. However, despite these concerns, a 
few studies have demonstrated the clinical benefits of 
TPE in severe COVID-19, and we believe that timely, 
appropriate application of TPE in selected cases 
presenting with cytokine storm could be beneficial. 
Since clinical deterioration of COVID-19 is 
mostly accompanied by worsening pneumonia and 
development of ARDS, we recommend initiating TPE 
when there are signs of respiratory failure requiring 
mechanical ventilation. In particular, highly elevated 
ferritin levels in blood, and the estimation of 
myocardial injury using high-sensitivity cardiac 
troponin I may also be considered useful [114, 115]. 
Severe COVID-19 is usually accompanied by 
hypotensive shock, which makes it difficult to 
maintain extracorporeal circulation. Therefore, it is 
better to start TPE early when blood pressure is 
maintained. In addition, referring to existing reports, 
we believe that TPE may be appropriate for use every 





day, or every other day. Previous reports have 
generally applied TPE two to three times in total; 
however, we believe that TPE can continue as long as 
there is no particular complication and exchangeable 
plasma is supplied smoothly. In addition, 
discontinuation may be considered if critical clinical 
conditions can be controlled by therapeutic methods 
other than TPE. In a few studies, two to 14 daily 
sessions, on average, were performed, with close 
monitoring of disseminated intravascular coagulation 
markers [116, 117]. A target calculated plasma volume 
exceeding 1 should be considered, and fresh frozen 
plasma is recommended to be used as a substitution 
fluid, due to the replenishment of anti-infective 
factors in serum. Ideally, convalescent plasma, if 
available, should be used, even if only at the end of a 
session [118-120]. Regarding existing TPE techniques, 
the centrifugal method might be preferable, as RCTs 
on TPE in septic shock have showed positive results 
with using centrifugation, although filtration types 
are also considered useful. Also, precise fluid 
overload control is necessary as decreasing vessel 
permeability is positive but can further impair 
pulmonary saturation. 
Conclusion 
 Cytokine storm is a severe clinical condition 
caused by systemic hyper-inflammation, resulting in 
severe injury to multiple organs, including the lungs, 
and even death. In that sense, anti-inflammatory 
treatment, along with anti-viral therapy, remains an 
important part of treatment for COVID-19. Currently, 
many anti-inflammatory agents have been attempted 
to treat severe COVID-19, and a large number of 
mixed results are being reported. With mounting 
evidence, we believe novel cytokine inhibitors, 
including tocilizumab, anakinra, and baricitinib, are 
promising options for treating severe COVID-19. 
In this review, we described TPE as a realistic 
alternative in the treatment of cytokine storm 
associated with COVID-19. We believe that TPE can 
have clinical benefits on severe COVID-19 when 
initiated promptly after early diagnosis based on 
rapid clinical deterioration and high inflammatory 
parameters, such as serum ferritin and 
high-sensitivity cardiac troponin I. We strongly 
recommend using TPE with convalescent plasma. 
Overall, we propose that TPE can be useful in 
combination with other potentially effective options 
for treating severe COVID-19. 
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